Jun 14, 2022 / 04:20PM GMT
Matthew Carlisle Sykes - Goldman Sachs Group, Inc., Research Division - Research Analyst
Good morning, everyone. Thanks for joining us. I'm Matt Sykes, the Life Sciences Tools and Diagnostics Analyst at Goldman Sachs. And this morning, we have the pleasure of welcoming senior management from Guardant Health, Helmy Eltoukhy and AmirAli Talasaz, the Co-Chief Executive Officers; and Michael Bell, the Chief Financial Officer.
Gentlemen, welcome. Thank you for joining us today.
Questions and Answers:
Matthew Carlisle Sykes - Goldman Sachs Group, Inc., Research Division - Research AnalystMaybe we could start out by just by having you set the stage for some key highlights in the first half of the year and maybe what investors should be focused on for the balance of '22?
Helmy Eltoukhy - Guardant Health, Inc. - Co-Founder, Co-CEO & Chairman
Yes. Thank you for having us here. It's always great to be in this wonderful venue. This has been really, I would say, instrumental and pivotal year for us in terms of